Key regions: France, India, United Kingdom, South Korea, Japan
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, causing symptoms such as muscle weakness, fatigue, and difficulty with coordination and balance. The Multiple Sclerosis Drugs market in Mongolia has been experiencing significant developments in recent years.
Customer preferences: Patients suffering from MS in Mongolia prefer treatments that are affordable and effective. They are willing to try new therapies that have shown promising results in clinical trials. However, due to the limited availability of healthcare services in the country, many patients are not able to access the latest treatments.
Trends in the market: The MS Drugs market in Mongolia has been growing steadily due to the increasing number of MS cases in the country. The demand for MS drugs is expected to rise further in the coming years due to the growing awareness of the disease and the availability of new treatments. The market has been witnessing a shift from traditional therapies to newer disease-modifying therapies (DMTs) that have shown better efficacy in treating MS.
Local special circumstances: Mongolia is a developing country with limited healthcare infrastructure. The availability of MS drugs is limited, and many patients have to rely on imported drugs. The high cost of imported drugs is a major challenge for patients, and the government is taking steps to improve access to affordable treatments. The country has a small population, and the market is highly concentrated, with a few major players dominating the market.
Underlying macroeconomic factors: The economic growth in Mongolia has been slow in recent years, and the healthcare sector has been facing budget constraints. The government is focusing on improving healthcare services in the country, and there is a growing demand for affordable and effective treatments for chronic diseases such as MS. The market is expected to grow in the coming years due to the increasing prevalence of MS and the availability of new treatments. However, the high cost of imported drugs and the limited availability of healthcare services in the country are major challenges for the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
